News

Ofatumumab is designed to target the CD20 molecule found on the surface of CLL cells and normal B lymphocytes. The sBLA, which was submitted by Novartis under Genmab’s

Lysogene and Alcyone Lifesciences will join forces to evaluate the intraparenchymal delivery of Lysogene’s proprietary rAAV to treat patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known as

Simulations Plus will continue to provide licenses for its GastroPlus, ADMET Predictor, and MedChem Studio software programs for use by the DNTP/NIEHS. The DNTP within the NIEHS is

Repatha is a human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver’s ability to remove LDL-C, or "bad" cholesterol, from the blood. Elevated LDL-C is

The study findings, which are being presented in a late-breaking oral presentation at the 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver, confirmed the antiretroviral

Neither the R&D goal that generated the milestone payment nor the amount were disclosed. The MvfR inhibitor program targets mechanisms of virulence and persistence in Pseudomonas and other

Iluvien is Alimera’s sustained release intravitreal implant designed for the treatment of diabetic macular edema (DME). Currently, Iluvien is not approved for sale in Canada. Iluvien (fluocinolone acetonide

The company said that BMS-663068 is an oral prodrug of the molecule BMS-626529 and first-in-class HIV-1 attachment inhibitor. BMS-663068 is designed to work differently than entry inhibitors, a

Dosing in this multi-center, open-label, dose-escalation trial has been carried out by the University of Virginia School of Medicine. The company is conducting the trial in collaboration with